Serge Menkin, MD
Interventional Pain Medicine · Jersey City, NJNPI 1881670784
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 197 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 32 manufacturers reported payments, led by Collegium Pharmaceutical, Inc. at 27.4% of the total. Reporting peaked in 2019 at $925 and has fallen 66.9% since, to $307 in 2025. That places this record below the midpoint for interventional pain medicine clinicians in NJ, where the typical reported total is $3,760.
Across 197 payments — averaging $17.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Collegium Pharmaceutical, Inc.$952
- Amgen$479
- Boston Scientific$233
- Globus Medical$195
- Nalu Medical, Inc.$153
- Vertos Medical, Inc.$140
- plus $1K from 26 others
What the payments were for
- Food & beverage$3,471100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 81 | $952 |
| Amgen | 28 | $479 |
| Boston Scientific | 4 | $233 |
| Globus Medical | 2 | $195 |
| Nalu Medical, Inc. | 2 | $153 |
| Vertos Medical, Inc. | 1 | $140 |
| Daiichi Sankyo Inc. | 14 | $121 |
| Biohaven Pharmaceuticals, Inc. | 1 | $115 |
| SPR Therapeutics, Inc | 3 | $113 |
| Medtronic | 1 | $110 |
| Scilex Pharmaceuticals Inc. | 7 | $97 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $93 |
| Biodelivery Sciences International, Inc. | 5 | $68 |
| Idorsia Pharmaceuticals US Inc | 4 | $67 |
| Pfizer | 5 | $65 |
| Almatica Pharma LLC | 5 | $64 |
| Indivior Inc. | 4 | $62 |
| Foundation Fusion Solutions, LLC | 4 | $53 |
| Sentynl Therapeutics, Inc. | 4 | $49 |
| Johnson & Johnson | 2 | $38 |
| Medline Industries LP | 1 | $33 |
| Virtus Pharmaceuticals LLC | 2 | $24 |
| Abbott | 1 | $18 |
| Zimmer Biomet | 1 | $18 |
| Kaleo, Inc. | 1 | $17 |
| Vertex | 1 | $15 |
| Pacira Pharmaceuticals Incorporated | 1 | $15 |
| Shionogi Inc | 1 | $15 |
| Spinefrontier, Inc. | 1 | $13 |
| Pernix Therapeutics Holdings, Inc. | 1 | $13 |
| Amneal Pharmaceuticals LLC | 1 | $12 |
| Bioventus LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RAYOS$375
- mild Device Kit$140
- VuePoint$132
- Nalu Neurostimulation System$125
- NURTEC ODT$115
- INCEPTIV$110
- GENERAL PAIN MANAGEMENT$104
How this compares
$3,471 in reported general payments places this provider in the 45th percentile of 82 interventional pain medicine providers in New Jersey.
See all interventional pain medicine providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RelistorMethylnaltrexone Bromide | 14 | $32,499 |
| Xtampza ErOxycodone Myristate | 41 | $30,700 |
| NucyntaTapentadol Hcl | 23 | $29,722 |
| MovantikNaloxegol Oxalate | 24 | $9,655 |
| Diclofenac Sodium | 94 | $9,479 |
| OxycontinOxycodone Hcl | 14 | $8,299 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 419 | $7,825 |
| Lidocaine | 53 | $6,293 |
| Oxycodone Hcl | 212 | $3,881 |
| Celecoxib | 93 | $1,997 |
| Doxepin Hcl | 27 | $1,521 |
| Cyclobenzaprine Hcl | 93 | $1,495 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 90 | $1,495 |
| Baclofen | 128 | $1,233 |
| Gabapentin | 126 | $1,051 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er, Nucynta | $952 | $60,42164 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $93 | $32,49914 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $97 | $68217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 82 interventional pain medicine providers in New Jersey.
Other interventional pain medicine in Jersey City
- Nicole BrandJersey City$2K
- Youssef JosephsonWest Deptford$496K
- Ali ValimahomedHolmdel$415K
- Saurabh DangEdgewater$157K
- Gabriele JasperBrick$114K
- Matthew LippChatham$67K
- Didier DemesminSomerset$33K
- Steve AydinFranklin Lakes$22K
- Kieran SlevinHainesport$21K
- John CoccaroToms River$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.